Among patients aged ≥ 65 years, pioglitazone showed a trend toward greater, although not statistically significant, HbA1c reduction compared with dapagliflozin at week 26 (− 1.04% vs. − 0.72%, p = 0.0477) (Supplementary Table S4 ).
← all excerpts
Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study.
1
—
—